Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease

A Practical Review of Proteasome Pharmacology

(2019) Tiffany A. Thibaudeau et al.   PHARMACOLOGICAL REVIEWS

Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression

(2019) Nicolas J. Lehrbach et al.   CELL

A Phase 1b/2 Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenström Macroglobulinemia

(2019) Irene M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2019) Jatin Shah et al.   Clinical Lymphoma Myeloma & Leukemia

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

(2019) Yan Song et al.   LEUKEMIA

Mitochondrial metabolism promotes adaptation to proteotoxic stress

(2019) Peter Tsvetkov et al.   Nature Chemical Biology

Targeting BTK in CLL: Beyond Ibrutinib

(2019) David A. Bond et al.   Current Hematologic Malignancy Reports

Targeted protein degradation: elements of PROTAC design

(2019) Stacey-Lynn Paiva et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

(2019) Ola Landgren et al.   LEUKEMIA

Selective Phenylimidazole-based Inhibitors of the Mycobacterium tuberculosis Proteasome

(2019) Wenhu Zhan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improving the cascade of global tuberculosis care: moving from the “what” to the “how” of quality improvement

(2019) Bruce D Agins et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2019) Parameswaran Hari et al.   LEUKEMIA RESEARCH

Oprozomib in patients with newly diagnosed multiple myeloma

(2019) Parameswaran Hari et al.   Blood Cancer Journal

Characterization of Fully Recombinant Human 20S and 20S-PA200 Proteasome Complexes

(2019) Ana Toste Rêgo et al.   MOLECULAR CELL

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Targeted protein degradation: expanding the toolbox

(2019) Matthieu Schapira et al.   NATURE REVIEWS DRUG DISCOVERY

Multisystem Proteinopathy Mutations in VCP/p97 Increase NPLOC4·UFD1L Binding and Substrate Processing

(2019) Emily E. Blythe et al.   STRUCTURE

Structure and Function of the 26S Proteasome

(2018) Jared A.M. Bard et al.   Annual Review of Biochemistry

Therapeutic peptides: Historical perspectives, current development trends, and future directions

(2018) Jolene L. Lau et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

(2018) Ronan T. Swords et al.   BLOOD

Resistance to proteasome inhibitors and other targeted therapies in myeloma

(2018) Craig T. Wallington-Beddoe et al.   BRITISH JOURNAL OF HAEMATOLOGY

Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection


(2018) Yanli Ding et al.   CLINICAL NEPHROLOGY

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

(2018) Nikoletta Lendvai et al.   LEUKEMIA & LYMPHOMA

VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling

(2018) Johannes van den Boom et al.   MOLECULAR CELL

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

(2018) Marc L Hyer et al.   NATURE MEDICINE

Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1–Npl4

(2018) Nicholas O. Bodnar et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The proteasome as a target to combat malaria: hits and misses

(2018) Karthik Mosur Krishnan et al.   Translational Research

Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration

(2018) Kwadwo A. Opoku-Nsiah et al.   Translational Research

Increased proteasomal activity supports photoreceptor survival in inherited retinal degeneration

(2018) Ekaterina S. Lobanova et al.   Nature Communications

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1–Npl4

(2018) Nicholas O. Bodnar et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Carfilzomib-Associated Cardiovascular Adverse Events

(2018) Adam J. Waxman et al.   JAMA Oncology

Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade

(2018) Yiwei Wang et al.   CELL RESEARCH

The immunoproteasome and thymoproteasome: functions, evolution and human disease

(2018) Shigeo Murata et al.   NATURE IMMUNOLOGY

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

(2018) Henry W. B. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production

(2017) Haijie Liu et al.   FASEB JOURNAL

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

(2017) Andrzej J. Jakubowiak et al.   Hematology

Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies

(2017) Nicole M. Valenzuela et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of an Inhibitor of the Proteasome Subunit Rpn11

(2017) Christian Perez et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Current State of Peptide Drug Discovery: Back to the Future?

(2017) Antoine Henninot et al.   JOURNAL OF MEDICINAL CHEMISTRY

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

(2017) Ronan Le Moigne et al.   MOLECULAR CANCER THERAPEUTICS

An AAA Motor-Driven Mechanical Switch in Rpn11 Controls Deubiquitination at the 26S Proteasome

(2017) Evan J. Worden et al.   MOLECULAR CELL

USP7 small-molecule inhibitors interfere with ubiquitin binding

(2017) Lorna Kategaya et al.   NATURE

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

(2017) Andrew P. Turnbull et al.   NATURE

Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11

(2017) Jing Li et al.   Nature Chemical Biology

Discovery and characterization of highly potent and selective allosteric USP7 inhibitors

(2017) Gerald Gavory et al.   Nature Chemical Biology

Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases

(2017) Linda Lauinger et al.   Nature Chemical Biology

A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function

(2017) Kapil V Ramachandran et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy

(2017) Emily E. Blythe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway

(2017) Mark A. Nakasone et al.   STRUCTURE

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets

(2017) Xiuxiu Lu et al.   Nature Communications

Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes

(2017) Ruda de Luna Almeida Santos et al.   Nature Communications

A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function

(2017) Kapil V Ramachandran et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity

(2017) Frederick M. Tomlin et al.   ACS Central Science

The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target

(2017) Philipp M. Cromm et al.   ACS Central Science

Azaindoles as Zinc-Binding Small-Molecule Inhibitors of the JAMM Protease CSN5

(2016) Eva Altmann et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome

(2016) Izidor Sosič et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Rational Design of Proteasome Inhibitors as Antimalarial Drugs

(2016) Camille Le Chapelain et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Mammalian proteasome subtypes: Their diversity in structure and function

(2016) Burkhardt Dahlmann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

(2016) S. J. Harrison et al.   CLINICAL CANCER RESEARCH

Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery

(2016) Kenneth Hallenbeck et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Ixazomib: First Global Approval

(2016) Matt Shirley   DRUGS

The cytoplasmic peptide: N -glycanase (NGLY1) — Structure, expression and cellular functions

(2016) Tadashi Suzuki et al.   GENE

Structure and function of the AAA+ ATPase p97/Cdc48p

(2016) Di Xia et al.   GENE

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

(2016) Jeffrey R. Infante et al.   INVESTIGATIONAL NEW DRUGS

Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes

(2016) Vanessa Welk et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression

(2016) Leah Randles et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma

(2016) Y Song et al.   LEUKEMIA

Proteome complexity and the forces that drive proteome imbalance

(2016) J. Wade Harper et al.   NATURE

Structure- and function-based design of Plasmodium-selective proteasome inhibitors

(2016) Hao Li et al.   NATURE

Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

(2016) Peter Tsvetkov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

2.3 A resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition

(2016) S. Banerjee et al.   SCIENCE

Gates, Channels, and Switches: Elements of the Proteasome Machine

(2016) Daniel Finley et al.   TRENDS IN BIOCHEMICAL SCIENCES

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo

(2016) Christa A. Manton et al.   Scientific Reports

Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1

(2016) Nicolas J Lehrbach et al.   eLife

The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction

(2016) Shun Koizumi et al.   eLife

Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome

(2016) Kyle A. Totaro et al.   ACS Infectious Diseases

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

(2016) Shuhang Wang et al.   Frontiers of Medicine

The Biology of Proteostasis in Aging and Disease

(2015) Johnathan Labbadia et al.   Annual Review of Biochemistry

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

(2015) J. Sarantopoulos et al.   CLINICAL CANCER RESEARCH

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

(2015) Denise Niewerth et al.   DRUG RESISTANCE UPDATES

A Reversible and Highly Selective Inhibitor of the Proteasomal Ubiquitin Receptor Rpn13 Is Toxic to Multiple Myeloma Cells

(2015) Darci J. Trader et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

(2015) Kaijun Di et al.   NEURO-ONCOLOGY

Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib

(2015) Wayne Harshbarger et al.   STRUCTURE

Thymoproteasomes produce unique peptide motifs for positive selection of CD8+ T cells

(2015) Katsuhiro Sasaki et al.   Nature Communications

Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome

(2015) Peter Tsvetkov et al.   eLife

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits

(2015) Diego Acosta-Alvear et al.   eLife

New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells

(2015) Hiroaki Kimura et al.   Journal of Immunology Research

Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities

(2015) Vivien Landré et al.   Oncotarget

Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes

(2014) Hao Li et al.   ACS Chemical Biology

Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation

(2014) Nicole S. Ejaz et al.   ANTIOXIDANTS & REDOX SIGNALING

Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy

(2014) Raymond J Deshaies   BMC BIOLOGY

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers

(2014) Seok Hoon Jang et al.   CLINICAL & EXPERIMENTAL METASTASIS

Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials

(2014) Zebo Huang et al.   Future Oncology

Label-Free Quantitative Proteomics Reveals the Dynamics of Proteasome Complexes Composition and Stoichiometry in a Wide Range of Human Cell Lines

(2014) Bertrand Fabre et al.   JOURNAL OF PROTEOME RESEARCH

Chemistry: Chemical con artists foil drug discovery

(2014) Jonathan Baell et al.   NATURE

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition

(2014) Senthil K Radhakrishnan et al.   eLife

Structural Biology of the Proteasome

(2013) Erik Kish-Trier et al.   Annual Review of Biophysics

Regulation of proteasome activity in health and disease

(2013) Marion Schmidt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Ubiquitin-independent proteasomal degradation

(2013) Jenny Erales et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

(2013) Ravi K. Anchoori et al.   CANCER CELL

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

(2013) Kyriakos P. Papadopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Acetylation-Mediated Proteasomal Degradation of Core Histones during DNA Repair and Spermatogenesis

(2013) Min-Xian Qian et al.   CELL

Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation

(2013) Christina Baum et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes

(2013) Kyung Bo Kim et al.   NATURAL PRODUCT REPORTS

The unique functions of tissue-specific proteasomes

(2013) Andrea Kniepert et al.   TRENDS IN BIOCHEMICAL SCIENCES

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity

(2012) Hao Li et al.   CHEMISTRY & BIOLOGY

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Understanding resistance to combination chemotherapy

(2012) Justin R. Pritchard et al.   DRUG RESISTANCE UPDATES

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system

(2012) Hemmo Meyer et al.   NATURE CELL BIOLOGY

Principles of Translational Control: An Overview

(2012) J. W. B. Hershey et al.   Cold Spring Harbor Perspectives in Biology

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?

(2012) Makoah Nigel Aminake et al.   International Journal for Parasitology-Drugs and Drug Resistance

AAA+ Proteases: ATP-Fueled Machines of Protein Destruction

(2011) Robert T. Sauer et al.   Annual Review of Biochemistry

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

(2011) D. J. Kuhn et al.   CURRENT CANCER DRUG TARGETS

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Protein homeostasis networks in physiology and disease

(2011) Claudio Hetz et al.   CURRENT OPINION IN CELL BIOLOGY

Proteasome inhibitor treatment of antibody-mediated allograft rejection

(2011) E. Steve Woodle et al.   Current Opinion in Organ Transplantation

Blm10 Protein Promotes Proteasomal Substrate Turnover by an Active Gating Mechanism

(2011) Thomas Dange et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

(2011) Pádraig D'Arcy et al.   NATURE MEDICINE

Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum

(2011) M. H. Smith et al.   SCIENCE

The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

(2011) P. Walter et al.   SCIENCE

Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients

(2011) William Robert Morrow et al.   TRANSPLANTATION

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes

(2010) Min Jae Lee et al.   MOLECULAR & CELLULAR PROTEOMICS

Structure of a Blm10 Complex Reveals Common Mechanisms for Proteasome Binding and Gate Opening

(2010) Kianoush Sadre-Bazzaz et al.   MOLECULAR CELL

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

(2010) Senthil K. Radhakrishnan et al.   MOLECULAR CELL

Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop

(2010) Janos Steffen et al.   MOLECULAR CELL

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

(2010) Byung-Hoon Lee et al.   NATURE

Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome

(2009) Daniel Finley   Annual Review of Biochemistry

The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity

(2009) B. Czesny et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

(2009) Han-Jie Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Proteasomes Can Degrade a Significant Proportion of Cellular Proteins Independent of Ubiquitination

(2009) James M. Baugh et al.   JOURNAL OF MOLECULAR BIOLOGY

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Abrogation of Anti-HLA Antibodies via Proteasome Inhibition

(2009) Hargovind L. Trivedi et al.   TRANSPLANTATION

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

TNF-α Induces Two Distinct Caspase-8 Activation Pathways

(2008) Lai Wang et al.   CELL

Comprehensive analysis of 20q13 genes in ovarian cancer identifiesADRM1as amplification target

(2008) Marlena S. Fejzo et al.   GENES CHROMOSOMES & CANCER

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction

(2008) Hwan-Ching Tai et al.   NATURE REVIEWS NEUROSCIENCE

IAP-targeted therapies for cancer

(2008) E C LaCasse et al.   ONCOGENE